United States · FDA National Drug Code directory
Firazyr
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 54092-702_19b83a10-9f38-4d0d-ae46-0f5b28168873
- Product NDC
- 54092-702
- Form
- INJECTION, SOLUTION
- Composition / generic term
- icatibant acetate
- Labeler
- Takeda Pharmaceuticals America, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20110825
- Source listing expiry
- 20261231
Source-listed ingredients
- ICATIBANT ACETATE — 30 mg/3mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE, GLASS in 1 CARTON (54092-702-01) / 3 mL in 1 SYRINGE, GLASS · 54092-702-01
- 1 SYRINGE, GLASS in 1 CARTON (54092-702-02) / 3 mL in 1 SYRINGE, GLASS · 54092-702-02
- 3 SYRINGE, GLASS in 1 CARTON (54092-702-03) / 3 mL in 1 SYRINGE, GLASS · 54092-702-03
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →